Repositioning GLP-1 Drugs for Neurologic Disease Including Alzheimer's and Parkinson's
Comprehensive review examining GLP-1 receptor agonists for neurological conditions. A recent NEJM trial showed GLP-1 treatment resulted in less motor disability progression at 12 months.